We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High-Sensitivity Troponin Demonstrates Potential for Diagnosing Acute Coronary Syndrome

By LabMedica International staff writers
Posted on 24 Sep 2024

Chest pain is a common yet difficult symptom for general practitioners to assess, as it can stem from both serious and benign conditions. More...

Now, a new study has found that high-sensitivity troponin tests have the potential to diagnose acute coronary syndrome in primary care settings.

In the study, researchers at the Leiden University Medical Center (Leiden, The Netherlands) evaluated the effectiveness of various risk assessment tools, including clinical decision rules and troponin tests, in helping general practitioners rule out acute coronary syndrome in patients presenting with chest pain. They conducted a systematic review of studies involving adult patients with chest pain in primary care. The review included studies that assessed the diagnostic accuracy of different clinical decision rules and troponin point-of-care tests, both conventional and high-sensitivity, for identifying acute coronary syndrome, including heart attacks. These tools were compared to the unaided clinical judgment of general practitioners.

The review, which included 14 studies, revealed that some clinical decision rules without troponin improved safety. However, none consistently outperformed the unaided judgment of general practitioners in ruling out acute coronary syndrome. Conventional troponin tests, when used alone, did not meet the required diagnostic accuracy, making them less reliable in primary care. High-sensitivity troponin tests demonstrated the greatest diagnostic accuracy but require further prospective validation in primary care before being recommended for widespread use. While these tests show promise, they are not yet ready to replace clinical judgment or be used independently without additional validation.

Related Links:
Leiden University Medical Center


Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Repetitive Pipette
VWR® Stepper Pro
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.